IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

  • End date
    Feb 20, 2023
  • participants needed
  • sponsor
    MedImmune LLC
Updated on 26 July 2021


The purpose of this study is to assess the safety and tolerability and to determine the dose of IPH5201 that can be used as monotherapy or in combination with durvalumab +/- oleclumab in subjects with advanced solid tumors.


Study D6770C00001 is a Phase 1, first-in-human, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, antitumor activity, pharmacokinetics, and immunogenicity of IPH5201 in adult subjects with advanced solid tumors, when administered as monotherapy or in combination with durvalumab oleclumab.

Condition Advanced Solid Tumors
Treatment durvalumab, oleclumab, IPH5201
Clinical Study IdentifierNCT04261075
SponsorMedImmune LLC
Last Modified on26 July 2021


Yes No Not Sure

Inclusion Criteria

Adult subjects; age 18 years
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Subjects diagnosed with advanced solid tumors
For Part 1 and Part 2 (IPH5201 in monotherapy or combined with durvalumab):Subjects must be refractory to standard therapy or for which no standard therapy exists
For Part 3 (IPH5201 combined with durvalumab and oleclumab): Subjects must have received and radiologically progressed on 1 prior line of systemic therapy for metastatic pancreatic ductal adenocarcinoma
Subjects must have at least 1 measurable lesion according to RECIST v1.1
Subjects must provide tumor specimens

Exclusion Criteria

Receipt of any conventional or investigational anticancer therapy (anti-CTLA-4, anti-PD-1, anti-PD-L1 antibodies) within 21 days of the planned first dose
Receipt of agents targeting CD73, CD39, or adenosine receptors
Concurrent enrollment in another therapeutic clinical study
Any toxicity (excluding alopecia) from prior standard therapy that has not been completely resolved to baseline at the time of consent
No toxicity leading to permanent discontinuation of prior IO therapy
Subjects must not have required the use of additional immunosuppression other than corticosteroids
Active or prior documented autoimmune or inflammatory disorders within the past 5 years
Cardiac and vascular criteria
Presence of myocardial infarction or unstable angina , or stroke, within 6 months
Congestive heart failure, serious cardiac arrhythmia requiring medication, or uncontrolled hypertension
History of severe hypertension
History of any grade of blood clot within 6 months
Active infection, including tuberculosis; hepatitis B virus (HBV); hepatitis C virus (HCV); or human immunodeficiency virus (HIV)
Uncontrolled illness including certain lung diseases, uncontrolled diabetes, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study
Other invasive malignancy within 2 years
Major surgery within 28 days prior to first dose
Female subjects who are pregnant or breast feeding
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note